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Infection is the outcome of a contest between a pathogen and its host. In the disease leishmaniasis, the causative protozoan
parasites are harbored inside the macrophages. Leishmania species adapt strategies to make the infection chronic, keeping a
balance between their own and the host’s defense so as to establish an environment that is favorable for survival and propagation.
Activation of peroxisome proliferator-activated receptor (PPAR) is one of the tactics used. This ligand-activated nuclear factor
curbs inﬂammation to protect the host from excessive injuries by setting a limit to its destructive force. In this paper, we report the
interactionofhostPPARsandthepathogenforvisceralleishmaniasis,Leishmaniadonovani,invivoandinvitro.PPARexpressionis
induced by parasitic infection. Leishmanial activation of PPARγ promotes survival, whereas blockade of PPARγ facilitates removal
of the parasite. Thus, Leishmania parasites harness PPARγ to increase infectivity.
1.Leishmaniasis
Leishmaniasis is caused by parasitic protozoa of the genus
Leishmania. The disease is found worldwide, with an esti-
mated prevalence of 12 million cases, 50,000 annual deaths,
and 350 millions of the world’s population at risk [1].
Leishmania has two stages in its life cycle: ﬂagellated pro-
mastigotes that live within the alimentary canal of the insect
vector and amastigotes that multiply within the phagolyso-
somesofmammalianmacrophages.Infectedfemalesandﬂies
introduce saliva and promastigotes into the mammalian
host during blood meals. The promastigotes are taken by
leukocytes and diﬀerentiate into intracellular amastigotes
within the macrophages. Then, infected macrophages carry
the parasites to diﬀerent organs. Over twenty species are
known to infect humans. The cutaneous species reside and
multiply within the skin tissue, whereas the visceral species
predominantly accumulate in the liver, spleen, and bone
marrow. These diverse species cause diﬀerent clinical mani-
festations, varying from self-healing or metastasizing skin
lesions to enlargement of visceral organs including the liver
andspleen.Thediseasesymptomsareclassiﬁedascutaneous,
mucocutaneous, or visceral leishmaniasis.
2.Resistance versusSusceptibility
Immunity against all species of Leishmania uniformly relies
on a type 1 immune response that produces interferon γ
(IFNγ). Produced by T helper 1 cells, IFNγ activates ma-
crophages to generate nitric oxide (NO), a free radical that
can kill Leishmania. Type 2 immune response, on the other
hand, is ineﬀective [2]. Production of interleukin-4 (IL-
4) in Leishmania major infection, regulatory T cells in L.
mexicana infection, and IL-10 in infection of various spe-
cies are all associated with susceptibility [2–6]. It is well
established that IL-4 exacerbates leishmaniasis when added
exogenously, and IL-10 mutant mice become resistant to
infection. However, to date, the reason why this cytokine
promotes the pathogenesis of Leishmania infection remains
partially understood [7–9].2 PPAR Research
3. M1 versusM2 inDiseasePathogenesis
Macrophages, the host of Leishmania parasites, are mark-
edly heterogeneous. When stimulated by IFNγ, these macro-
phages diﬀerentiate into the classically activated (M1) phe-
notype, with inducible nitric oxide synthase (iNOS) which
produces NO from arginine. Intracellular Leishmania para-
sites are eliminated by this subpopulation. On the contrary,
IL-4 diﬀerentiates macrophages towards the alternatively
activated (M2) phenotype, which promotes humoral immu-
nity and tissue repair. This subpopulation produces IL-10,
and transforming growth factor-β (TGF-β), [10].
In terms of signaling, IL-4 induces the expression of
PPARγ and PPAR gamma coactivator-1 (PGC-1) β protein
through the STAT-6 pathway [12]. This nuclear regulator
polarizes the monocytes into alternatively activated (M2)
macrophages with anti-inﬂammatory properties. By its tran-
scriptional activity, it mediates the expression of arginase-
1 (Arg1) and CD36 [13, 14]. Arginine metabolism away
from production of NO compromises the ability of infected
macrophage to clear the intracellular pathogens [2, 11]. CD-
36 is a scavenger receptor that mediates phagocytosis and
facilitatestheremovalofapoptoticcells.Byitstransrepressive
action, PPARγ blocks the expression iNOS as well as nu-
clear factor kappa B (NFκB)-mediated transcription of pro-
inﬂammation mediators [15].
4.Leishmania donovani InfectionInducesHost
PPAR GeneExpression In Vivo andIn Vitro
Our laboratory has been studying the pathogenesis of
Leishmania,withparticularinterestin L.donovani.W ein v es-
tigated whether susceptibility to infection is associated with
the activation of PPAR [16]. Mice of the susceptible BALB/c
strain were infected with stationary phase promastigotes of
L. donovani. After four weeks, their liver and spleen were
excised, and PPARα and γ mRNA levels were analyzed, using
the technique of quantitative real-time RT-PCR. Infection
of Leishmania l e a d st oi n c r e a s ei nP P A Rg e n ee x p r e s s i o n .
We detected 3-fold increase in mRNA of PPARα in the liver
(Figure 1(a)) and 3-fold increase for PPARγ in the spleen
(Figure 1(b)), as compared to the uninfected control organs.
At the cellular level, when residential macrophages from
peritoneal exudates of BALB/c mice were infected, PPARγ
gene expression was also increased. The increase of PPARγ
mRNA was 2-fold for Leishmania-infected peritoneal exu-
datecells(PECs)(Figure 1(c)).Kineticsstudywasperformed
to examine whether PPAR expression correlates to parasite
burden (Figure 2). The expression of PPARγ in the liver was
found to be slightly ahead of the increase in parasites burden
(Figure 2(a)). Both PPARγ and parasite number peaked at
4 weeks, which is the time when granuloma will form and
parasitegrowthwillbequenched.Astheinfectionintheliver
decreases, the expression of PPARγ subsides in coordination.
In the spleen where the parasites will persist, the rise in
PPARγ expression correlates closely with the increase in
parasite number (Figure 2(b)). Both parameters followed a
logarithmic increase between weeks 2 to 4 until reaching a
plateau at week 6.
5.Possible Mechanismsby WhichLeishmania
I nd uc e sPP A RGe neExp r e ssio n
PPAR is a genetic sensor of fatty acids, and its ligands are
produced during the course of Leishmania infection. Cy-
clooxygenase-2 (COX-2) is an enzyme that converts ara-
chidonic acid into various bioactive lipids, including pros-
taglandin (PG) D2,P G E 2,P G F 2, thromboxane (TX) B2, 15d-
PGJ2, and prostacyclin. Studies in the murine model of L.
donovani infection have demonstrated that production of
these bioactive lipids is enhanced upon infection [18, 19],
and studies with L. amazonensis have revealed that COX-2 is
neededforestablishinginfection[20].Blockade ofCOX with
indomethacin inhibits L. amazonensis infection of peritoneal
macrophages in vitro and reduces the size of lesions in
susceptible BALB/c mice.
Among the COX-2 products 15d-PGJ2 is a potent endo-
genous ligand for PPAR [21]. Moreover, in vitro addition of
PGE2 increases the number of amastigotes within macro-
phages [22]. PGE2 can activate the generation of lipoxins, a
relatively new class of eicosanoids that are also derived from
arachidonic acid, but through lipoxygenase or acetylated
COX instead [23, 24]. Lipoxin will shut oﬀ inﬂammatory
response when bound to its receptor [25]. In L. major infec-
tion, addition of exogenous lipoxin A4 increases infectivity;
this eﬀect has been conﬁrmed by receptor inhibition studies
[26]. The eicosanoid downregulates inﬂammation by pro-
moting clearance of apoptotic neutrophils [25]. Leishmania
parasites(L.major,L.donovani,L.mexicana,etc.)arecovered
with phosphatidylserine (PS), a major surface characteristic
of apoptotic cells, and engulfment of apoptotic cells leads
to induction of PPAR [27, 28]. For these reasons, the
parasitized macrophages would have activated PPAR and are
likely to express an alternatively activated (M2) phenotype.
Furthermore, PPAR turns on the expression of CD36, and
this scavenger receptor would bind to thrombospondin and
facilitate phagocytosis of the apoptotic neutrophils [29], the
so-called Trojan horses for Leishmania parasites at the site
of inoculation, reciprocally in a positive feedback manner
[30–32]. Ligand activation of PPARγ augments phagocytic
capacity of the alternatively activated macrophages.
6. Blockade of PPAR Reduces
Leishmania Infection
Since PPAR is upregulated with Leishmania infection, we
proceeded to determine whether the activation of PPAR is
essential for infection. Studies assessing the eﬀect of PPAR
blockade on Leishmania infectivity have been conducted
with L. major. Our laboratory studied L. donovani using
PECs from the C57BL/6 mice, a strain that is susceptible
to L. donovani infection though not L. major.Ar e a s o nf o r
selecting this strain is that it does not have a deﬁciency in T
helper 1 cells and thus is capable of producing IFNγ,w h i c h
is necessary for generation of the parasiticidal NO molecule.
Nonelicited residential macrophages from the peritoneum
were infected with L. donovani promastigotes, and IL-4 was
added to activate PPARγ [33]. Then, PPARγ transcriptionalPPAR Research 3
0
1
2
3
4
5
6
P<0.005
Ld
P
P
A
R
α
/
1
8
S
R
N
A
+ −
(a) Liver
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
P<0.001
Ld
P
P
A
R
γ
/
1
8
S
R
N
A
+ −
(b) Spleen
0
0.5
1
1.5
2
2.5
3
Ld
P<0.01
+ −
(c) PEC
Figure 1: Leishmania infection activates PPAR gene expression. In (a) and (b), BALB/c mice were infected i.v. with 107 stationary phase
promastigotes of L. donovani for 4 weeks, and then liver and spleen, respectively, were harvested. In (c), peritoneal exudate cells (PECs) were
obtained from the peritoneum of normal BALB/c mice, infected with L. donovani at 1 : 10 ratio, and then harvested for RNA isolation
after 2 days. PPAR activation was measured by real-time RT-PCR with normalization to 18S or actin RNA, and modulation was compared
and expressed relative to the uninfected control using the delta-delta Ct method. The infected groups (black bars) showed higher levels of
gene expression in liver (a), spleen (b), and PECs (c) in comparison to uninfected controls (open bars). Statistical analysis was performed by
Mann-Whitney U test, and a P value of less than 0.05 was considered as signiﬁcant.
activitywasblockedwithSR202,anantagonistwhicheﬃcacy
and speciﬁcity have been shown in adipocytes [34–36]. The
eﬀect of PPARγ on parasite survival and proliferation in the
host macrophages was assessed by enumerating the number
of amastigotes per macrophage. In the absence of IL-4,
the number of amastigotes per infected macrophage was
4.94±0.44(Figure 3(b)).IL-4activatedPPARγ (Figure 3(a)),
and this resulted in an increase in infectivity (Figure 3(b)).
There were 7.10 ± 1.82 amastigotes per macrophage. This
enhancement by IL-4 was reversed by blocking PPARγ
(Figure 3(b)). Addition of SR202, at 25 and 50μM, in a dose-
dependent manner, reduced the number of amastigotes per
macrophage to 5.05 ± 1.38 and 2.02 ± 0.81, respectively.
This reduced infection was further correlated to an increase
in nitric oxide level in the cultures (Figure 3(c)). The eﬀect
of SR202 at 50μM or lower is speciﬁc to the infectious
process for, at these concentrations, the compound did not
aﬀect the survival of promastigotes or mammalian cells
(Figures 3(d) and 3(e)). Figure 4 shows the cultures that had
been stained with Diﬀ-Quik for microscopic enumeration.
The macrophages that had been treated with 50μMo f
SR202 presented a healthy morphology with many empty
parasitophorous vacuoles freed of parasites.
Complementary results were obtained with Leishmania
major in bone marrow-derived macrophages from the resis-
tant C57BL/6 mice in a study by Gallardo-Soler et al. (2008).
The PPAR antagonists, GW9662 and GW5393, reduce infec-
tivity [13]. Whereas we correlated PPAR activity in our L.
donovani infection to the transrepressive action on iNOS-
mediated NO production (Figure 3), this study correlated
infectivity to the transcription of arginase. The enzyme is
a bona ﬁde marker for PPAR-mediated transcription and
alternatively activated (M2) macrophages. Its mRNA level
was decreased in coordination to the decrease in infection.
In addition to pharmacological inhibitors, Odegaard et al.
(2007) have examined L. major infectivity in mice with ma-
crophages that do not express PPARγ (Mac-PPARγ KO,
PPARγﬂ/ﬂ LysMcre)[37].Themutantmiceha v eimpair edM2
macrophage activation, a delayed disease progression, and a
lower parasite load (less footpad swelling) compared to the
wild type [37]. Henceforth, PPARγ plays an essential role in
the pathogenic process of both L. major and L. donovani.
In the absence of PPARγ activity, the balance shifts from
the arginase producing M2 phenotype to that of nitric oxide
producing, type 1, response.
7. PPAR ActivationEnhances
Leishmania Infection
Conversely, Gallardo-Soler et al. (2008) also demonstrated
that the PPAR agonists GW1929 and GW7845 (for PPARα)
and GW0742 (for PPARγ), at 1μm concentration, increased4 PPAR Research
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Figure 2: Kinetics of PPAR expression and parasitic infection. BALB/c mice were intravenously injected with 107 stationary phase
promastigotes of L. donovani 1S. At two-week intervals, groups (n = 5) were sacriﬁced, and their liver and spleen were harvested. PPAR
expression was determined by real-time RT-PCR as described in legend of Figure 1. The amount of parasites in the organs was determined
by limiting dilution analysis according to the procedure of Titus and colleagues [17]. Cells were plated into wells of 96-well plates at a range
of concentrations, according to the number of red blood cells in the liver and splenocytes in the spleen suspensions and then incubated at
27◦C to allow the parasites to transform from intracellular amastigotes into promastigotes. After 2-3 weeks of proliferation, the number of
wells that shows parasite growth was scored under a microscope, and the L-Calc software for limiting dilution analysis (provided by Stem
Cell Technology, Vancouver, Canada) was used to determine the frequency of parasite. Normalization was based on the number of red blood
cells in the liver cultures (a) and the number of splenocytes in the spleen cultures (b).
intracellular growth of Leishmania major in bone marrow-
derived macrophages [13]. When both PPAR/RXR ligands
were coadministered, the degree of infection was similar to
those infectedin the presenceof IL-4. This increased number
of intracellular amastigotes can be correlated to the levels of
arginase activity.
PPAR is also regarded as dietary-sensing nuclear recep-
tors; many activators of PPARγ have been identiﬁed in
foods [38]. Our laboratory is interested in the eﬀect of cur-
cumin (Figure 5), a dietary activator of PPARγ on visceral
leishmaniasis [16, 39]. It is the active principle in the spice
turmeric, which is used abundantly in India, where visceral
leishmaniasis is endemic in the Bihar region. Curcumin
is well known for its anti-inﬂammatory eﬀect, and there
is ample evidence that the activity can be attributed to
the activation of PPARs [40–43]. Zheng and Chen (2007)
have suggested that there is a curcumin-responsive element
residing in the regulatory region of the PPARγ gene [44].
We examined the eﬀect of curcumin on PPAR activation
and Leishmania infection in vivo [16]. Susceptible BALB/c
mice and resistant C3H mice were infected with L. dono-
vani; immediately following inoculation, the mice were
fed curcumin or phosphate-buﬀered saline (PBS) every
other day. Then, at 4 weeks after infection, the livers and
spleens were harvested and quantiﬁed for PPARγ,i N O S ,
cytokines, and parasite load. Parasite load was quantiﬁed by
two complementary methods, limiting dilution analysis and
real-time PCR detection, and compared by the parametric
test ANOVA after data transformation. Figure 6 shows the
results on PPARγ,i N O S ,a n dLeishmania kinetoplast DNAPPAR Research 5
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Figure 3: Blocking PPARγ activation with an antagonist reduces L. donovani infectivity. In (a), peritoneal exudate cells were infected by L.
donovani using a 1 to 10: PEC to promastigote ratio. The cultures were incubated with 4ng/mL of IL-4 for 24 hours, then total RNA was
harvested, and RT-PCRs were performed to quantify the copies of PPARγ and β-actin mRNA as described in Adapala and Chan [16]. In (b),
PECsfromC57/BL6micewereattachedtocoverslipsandinfectedwithL.donovanipromastigotesat1:5ratio.After20to24hours,5ng/mL
of IL-4 and various concentration of SR202 were added. The infection was allowed to develop at 37◦Ci na5 %C O 2 incubator for another 3
days.Then,thecoverslipswereﬁxedinmethanolandstainedwithDiﬀ-Quik.Thedegreeofparasiteburdenwasdeterminedbyenumeration
under a microscope in a double-blind manner by at least two individuals. Uninfected macrophages, infected macrophages, and the number
of amastigotes in these macrophages were counted. The result is reported as amastigotes/macrophage, and each data point was derived from
counting at least about one hundred macrophages or one hundred infected macrophages, as appropriate. (c) shows the levels of nitric oxide
in PECs that were similarly infected with L. donovani promastigotes, except that IFNγ was added instead of IL-4 to stimulated inducible
nitric oxide synthase expression. On day 5, the amount of nitric oxide was determined with Griess reagent. Shown are the relative levels of
nitrite, oxidized form of nitric oxide, in the culture supernatants. In (d), SR202 was added to freshly harvested, uninfected PECs and bone
marrow cells at various concentrations. After 3 days, the number of live cells was determined by counting with trypan blue. In (e), SR202
was added to promastigotes, and after 5 days of proliferation, the number of parasites was determined by counting under a microscope. The
results shown are representative of three independent experiments.6 PPAR Research
Uninfected PEC L. donovani +I L - 4
L. donovani L. donovani + IL-4 + SR202 (50μM)
Figure 4: Morphology of the peritoneal macrophages after SR202 treatment. Micrograph of cover slips from the cultures described in
Figure 3(b). The black arrows point to macrophages with phagolysosomes ﬁlled with amastigotes. The black arrows point to infected
macrophages and the red arrow points to infected macrophages with phagolysosomes cleared of amastigotes.
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Figure 5: Chemical structure of curcumin.
quantiﬁcation. Curcumin treatment led to 5-fold increase in
the gene expression for PPARγ and 2-fold increase in the
gene expression for PPARγ in the spleen. It also caused an
80% decrease in the expression of iNOS in the liver and
68% in the spleen (Figures 6(a)and 6(b)). Concomitant with
these modulations, parasite burden was elevated compared
to the untreated vehicle control, (results from limiting
dilution were not shown).
Corresponding to the feeding studies, we found that
curcuminincreasedPPARγ anddecreasediNOSgeneexpres-
sion in infected macrophages. At 10μm, curcumin increased
PPARγ mRNA levels in infected peritoneal macrophages
from BALB/c by 1.5-fold Figure 7(a). The dose dependency
of the curcumin actions was demonstrated by iNOS gene
expression and nitric oxide production. The level of gene
expression is shown in Figure 7(b).A t1 0 μm, curcumin
reduced the level of steady-state RNA by 70%. The level of
nitric oxide in the culture supernatants was also reduced.
At 5, 7.5, and 10μm of curcumin, the reduction was
18, 39.3, and 61.4%, respectively [16]. In parallel to the
reduction, parasite infectivity increased. The number of
infected macrophages increased dose dependently from 28
to 37% in the resistant C3H strain and from 35 to 48% in
the susceptible BALC/c strain. The number of amastigotes
per macrophage also increased dose dependently, as shown
in the table in Figure 7(c).
8. Conclusion: Mechanismsof
PPARs on Leishmaniasis
Taken together, these cumulative data from L. donovani
and L. major infections indicate that PPAR plays a role in
leishmaniasis, no matter in the liver where the PPARα forms
predominate,inthespleenandresidentialmacrophagesfrom
the peritoneum or the bone marrow where the PPARγ forms
predominate[46].Ourperspectiveonhowthenuclearfactor
is activated during infection and how its activation enhances
the survival of Leishmania parasites is as follows. When the
infected sandﬂies bite, an inﬂammatory reaction initiatesPPAR Research 7
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Figure 6: Activation of PPAR enhances parasitic infection. Mice were infected with L. donovani. One group was fed with 0.2mL freshly
prepared curcumin solution, given by oral gavage every other day throughout the course of the study. Curcumin was dissolved to a solution
of 7.52mg/mL in 0.1N NaOH and immediately brought to pH 7.2 by diluting to a concentration of 11.1μg/mL in PBS. The second group
received phosphate buﬀered saline (PBS) in the same manner. At 4 weeks, the peak of hepatic infection (as shown in Figure 2), livers, and
spleens were harvested for DNA and RNA extractions. PPAR and iNOS expression were determined by real-time RT-PCR and normalized
to 18S RNA. Parasite load in the liver and spleen was determined by the real-time PCR procedure which was that of Nicolas and colleagues
[45], except the reaction occurred in SYBR Green I PCR master mix (from Superarray). DNA, at 40ng per reaction, was denatured at 95◦C
for 10min, and then Leishmania kinetoplast DNA (kDNA) was ampliﬁed in a thermal cycler (Rotor-gene 6.0, from Corbett). The number of
copies of kDNA per μg of DNA was determined using a standard curve that was established with the cloned PCR product. Filled diamonds
were curcumin-treated, and clear circles were saline controls. N indicates the number of mice in each group. Statistic analysis was performed
by ANOVA after the data underwent natural log transformation as described in Adapala and Chan [16]. A P value of <0.05 was considered
as signiﬁcant.
innate and adaptive immune response for protection against
the parasites. Neutrophils and macrophages are recruited to
the injection site, and promastigotes enter the phagocytes.
Launching a type 1 immune reaction, with production of
nitric oxide, would resist infection. However, the parasites
and infected host cells can synthesize ligands that activate
PPARγ. Phagocytosis of apoptotic neutrophils and IL-4
from T helper 2 cells can do so as well. With the activa-
tion of PPARγ, Leishmania parasites would beneﬁt from
inﬁltration of macrophages, inactivation of the destructive
inﬂammatory response, and promotion of the resolution of
inﬂammation. Activation of PPAR promotes diﬀerentiation8 PPAR Research
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Figure 7: Curcumin induces PPARγ mRNA expression and reduces iNOS mRNA expression in infected macrophages. In (a), PECs of
BALB/c mice were infected with L. donovani promastigotes, and then 10μM of curcumin (brown bar) or vehicle control (0.1% acetone)
was added. After 2 days, the cells were harvested for RNA isolation to determine the level of PPARγ and β-actin expression by real-time
RT-PCR. In (b), murine RAW264.7 cells were infected with L. donovani for 16–20 hours. Then, diﬀerent concentrations of curcumin were
added. Thirty minutes after curcumin treatment, IFNγ was added to activate the macrophages. At 5 hours after the addition of IFNγ,t h e
cells were harvested, mRNA was extracted, and conventional RT-PCR was performed. The gel shows the end point PCR-ampliﬁed iNOS
(496bp) and β-actin cDNAs products. In (c), nonelicited PECs from resistant C3H and susceptible BALB/c strains were cultured with L.
donovani promastigotes in wells that contained cover slips for a period of 16–20 hours; then curcumin and IFNγ and TNFα were added. On
day 4-5, the coverslips were stained to enumerate the percent of infected macrophages and number of amastigotes per macrophage under a
microscope, similar to steps described in Figure 3.
ofthehostmacrophagesintothealternativelyactivated(M2)
macrophages, which have a type 2 phenotype and would
producearginasetointerferewithenzymaticactivityofiNOS
[47]. As such, the parasites can survive and multiply within
the host’s macrophages, and the infection becomes chronic
(Figure 8).
Currently, whether antagonists of PPAR would be thera-
peutic for leishmaniasis remains to be investigated. SR202,
the antagonist that we used in our study, has been shown
to prevent obesity in rats and therefore has in vivo eﬃcacy.
Ligands for PPARγ are drugs for type 2 diabetes, and ligands
for PPARα are also currently in clinical use for obesity. HowPPAR Research 9
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Figure 8: Scheme of Leishmania interaction with mediators of the resolution process during inﬂammation. When infected sandﬂies bite,
promastigotes enter the neutrophils and macrophages that are recruited to the inﬂamed site of injection. The parasite can, by itself, activate
the infected host cells to produce PPAR activators. This includes PPARγ agonists such as the bioactive lipids 15d-PGJ2 and LXA4 from the
arachidonic acid pathways. Engulfment of apoptotic neutrophils and IL-4 from T helper 2 cells can activate PPARγ as well. Activation of
PPARγ polarizes the host macrophage towards the alternatively activated macrophage (M2) phenotype, which would produce arginase to
divert substrate from iNOS and thus reduce the production of nitric oxide. As such, the parasite can survive and multiply within the host’s
macrophages, and the infection becomes chronic.
would these agents aﬀect the outcome of leishmaniasis and
whether PPAR aﬀects the survival of other parasites are
interesting questions [46].
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